Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

Regeneron has been looking to switch patients ... This unique collaboration will see the Meningitis Flag — a powerful symbol of the global fight ag Roche beat first-quarter sales expectations ...

It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Shares of Regeneron Pharmaceuticals Inc. REGN rallied 2.65% to $605.61 Friday, on what proved to be an all-around favorable ...

Shares of Regeneron Pharmaceuticals Inc. REGN slipped 1.46% to $590.00 Thursday, on what proved to be an all-around positive ...

Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the Zacks Consensus Estimate of $8.43. The reported figure was down 14% ...

Regeneron (REGN) came out with quarterly earnings of $8.22 per share, missing the Zacks Consensus Estimate of $8.43 per share. This compares to earnings of $9.55 per share a year ago. These ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was ...

April 29 (Reuters) - Regeneron's (REGN.O), opens new tab first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker. Over the first three months of 2025, Regeneron's ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was 3% ...